Get started
Author

John Leyden

Observed names: J. Leyden, J.C. Leyden, John Charles Leyden, John Leyden (13470340)
Institution: Cancer Australia
Observed institutions: Albert Einstein College of Medicine, Uppsala University Hospital, University of Toronto, Royal North Shore Hospital, Wesley Hospital, Cancer Australia, Northern Sydney Local Health District, Icahn School of Medicine at Mount Sinai
ORCID: 0000-0002-3913-5960
Observed ORCIDs: 0000-0002-3913-5960, 0000-0002-1023-1959
OpenAlex ID: A5085397064
Placebo‐controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression
2016 · C. K. Loo, V. Gálvez, et al. · Acta Psychiatrica Scandinavica · 263
Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs
2016 · Simron Singh, Dan Granberg, et al. · Journal of Global Oncology · 165
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression
2017 · Duncan George, Verònica Gálvez, et al. · American Journal of Geriatric Psychiatry · 152
Pilot dose–response trial of i.v. ketamine in treatment-resistant depression
2014 · Rosalyn Lai, Natalie Katalinic, et al. · The World Journal of Biological Psychiatry · 112
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial
2023 · Colleen Loo, Nicholas Glozier, et al. · The British Journal of Psychiatry · 87
PDF
Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States
2017 · Edward M. Wolin, John Leyden, et al. · Pancreas · 60
The Anaesthetic-ECT Time Interval in Electroconvulsive Therapy Practice – Is It Time to Time?
2015 · Verònica Gálvez, Dusan Hadzi-Pavlovic, et al. · Brain stimulation · 43
Long-Lasting Effects of a Single Subcutaneous Dose of Ketamine for Treating Melancholic Depression: A Case Report
2014 · Veronica Gálvez, Emily O’Keefe, et al. · Biological Psychiatry · 40
Effects of the Anaesthetic-ECT time interval and ventilation rate on seizure quality in electroconvulsive therapy: A prospective randomised trial
2019 · Rohan Taylor, Harry Wark, et al. · Brain stimulation · 24
PDF
First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs).
2020 · Nick Pavlakis, David Turner Ransom, et al. · Journal of Clinical Oncology · 20
The Economic Impact on Australian Patients with Neuroendocrine Tumours
2020 · Louisa G. Gordon, Thomas M. Elliott, et al. · Patient · 19
The anaesthetic-ECT time interval with thiopentone—Impact on seizure quality
2019 · Rohan Taylor, Dusan Hadzi-Pavlovic, et al. · Journal of Affective Disorders · 12
PDF
Patient‐reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey
2017 · John Leyden, Nick Pavlakis, et al. · Asia-Pacific Journal of Clinical Oncology · 10
PDF
Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy
2022 · Minmin Li, David L. Chan, et al. · Neuroendocrinology · 9
Patient-reported time to diagnosis of neuroendocrine tumors (NETs) in Europe: results from the first global NET patient survey: a collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis
2015 · Marianne Pavel, Teodora Kolarova, et al. · Endocrine Abstracts · 6
PDF
Lung neuroendocrine tumor (NET) patient (pt)-reported experience: Results from the first global NET pt survey—A collaboration between the international neuroendocrine cancer alliance (INCA) and Novartis pharmaceuticals.
2015 · Dan Granberg, Maia Sissons, et al. · Journal of Clinical Oncology · 5
[177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial
2026 · David L. Chan, Katrin Marie Sjoquist, et al. · European Journal of Cancer · 4
Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention
2019 · Lisa Guccione, Karla Gough, et al. · JMIR Research Protocols · 4
PDF
The time interval between anaesthetic induction and the ECT stimulus – It’s time to time!
2015 · V. Gálvez, D. Hadzi-Pavlovic, et al. · Brain stimulation · 3
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial – CORRIGENDUM
2024 · Colleen Loo, Nick Glozier, et al. · The British Journal of Psychiatry · 1
PDF
Neuroendocrine tumor (NET) patient (pt) experience with disease management: Results from the first global NET pt survey—A collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis.
2015 · Simron Singh, Grace Goldstein, et al. · Journal of Clinical Oncology · 1
Neuroendocrine tumor European patient experience: results from the first global NET patient survey - a collaboration between the International Neuroendocrine Cancer Alliance and Novartis
2015 · Kjell Oberg, John Leyden, et al. · Endocrine Abstracts · 1
PDF
Quantifying the Net Patient Experience Through the First Global Net Patient Survey: a Collaboration Between the International Neuroendocrine Cancer Alliance and Novartis
2014 · T. Kolarova, M. Sissons, et al. · Annals of Oncology · 1
PDF
Don't hold your breath - it's time to stimulate!
2019 · R. Taylor, H. Wark, et al. · Brain stimulation
Neuroendocrine Tumor (net) Oceania Patient Experience: Results From the First Global Net Patient Survey - a Collaboration Between the International Neuroendocrine Cancer Alliance (inca) and Novartis
2015 · John Leyden, Nick Pavlakis, et al. · Figshare
Works count: 33
Citation count: 1,043
H-index: 12
I10-index: 13
Year
Topic
Type